Gene analysis in melanoma patients using circulating tumor DNA
| Project/Area Number |
26461687
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
ASHIDA Atsuko 信州大学, 学術研究院医学系, 助教 (00596786)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
宇原 久 札幌医科大学, 医学部, 教授 (40201355)
奥山 隆平 信州大学, 学術研究院医学系, 教授 (80292332)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | ctDNA / メラノーマ / BRAF / NRAS / バイオマーカー / circulating tumor DNA |
|---|
| Outline of Final Research Achievements |
Circulating tumor DNA (ctDNA) is a novel biomarker for evaluating the features of tumors in cancer patients. Detection of ctDNA usually requires specialized equipment, because blood includes only a small amount of the tumor- derived DNA. We assessed the utility of BRAF- and NRAS mutated ctDNA levels using competitive allele specific TaqMan PCR (castPCR) or droplet digital PCR. ctDNA was detected in cases with heavy tumor burden as advanced disease. Detection of ctDNA was associated with poor prognosis. Quantification of ctDNA (BRAFmutant or NRASmutant) levels during the treatment course (nivolumab or vemurafenib) showed dynamic changes corresponding to radiologic and clinical alterations. Our finding suggest that ctDNA might be a useful biomarker of clinical response and tumor recurrence while monitoring patients with metastatic melanoma.
|
Report
(4 results)
Research Products
(28 results)
-
-
-
-
-
-
-
[Journal Article] Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.2015
Author(s)
Sakaizawa K, Ashida A, Uchiyama A, Ito T, Fujisawa Y, Ogata D, Matsushita S, Fujii K, Fukushima S, Shibayama Y, Hatta N, Takenouchi T, Uehara J, Okuyama R, Yamazaki N, Uhara H.
-
Journal Title
J Dermatol Sci.
Volume: 80
Issue: 1
Pages: 33-37
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
